Compare · BGLC vs HUM
BGLC vs HUM
Side-by-side comparison of BioNexus Gene Lab Corp (BGLC) and Humana Inc. (HUM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BGLC and HUM operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $46.74B, about 12805.6x BGLC ($3.7M).
- Over the past year, BGLC is down 68.8% and HUM is up 63.3% - HUM leads by 132.1 points.
- HUM has hit the wire 3 times in the past 4 weeks while BGLC has been quiet.
- HUM has more recent analyst coverage (25 ratings vs 0 for BGLC).
- Company
- BioNexus Gene Lab Corp
- Humana Inc.
- Price
- $1.54-21.83%
- $388.90-1.42%
- Market cap
- $3.7M
- $46.74B
- 1M return
- -28.04%
- +7.58%
- 1Y return
- -68.83%
- +63.26%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 3
- Recent ratings
- 0
- 25
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Latest BGLC
- BioNexus Gene Lab Corp filed SEC Form 8-K: Other Events, Regulation FD Disclosure, Financial Statements and Exhibits
- BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development
- SEC Form 10-Q filed by BioNexus Gene Lab Corp
- SEC Form 10-K filed by BioNexus Gene Lab Corp
- SEC Form NT 10-K filed by BioNexus Gene Lab Corp
- BioNexus Gene Lab Corp filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
- BioNexus Gene Lab Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
- BioNexus Gene Lab Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest HUM
- Humana upgraded by Wells Fargo with a new price target
- SEC Form 4 filed by Director Hilzinger Kurt J
- The Humana Foundation Deepens Investment in Emotional Health, Announcing Over $12 Million in New Grants
- SEC Form 11-K filed by Humana Inc.
- SEC Form 11-K filed by Humana Inc.
- Humana Inc. to Release Second Quarter 2026 Results on July 29, 2026
- Humana Awarded Statewide Illinois HealthChoice Medicaid Contract, Expanding Access to Care Across the State
- Humana Announces Agreement to Divest Minority Interest in Gentiva
- Humana Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Humana completes $83 million Florida infrastructure investment to deepen coordinated patient care approach